本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Agios Pharmaceuticals, Inc.

36.01
-0.1200-0.33%
盤後36.010.00000.00%18:37 EDT
成交量:148.16萬
成交額:5,456.72萬
市值:20.92億
市盈率:3.24
高:37.91
開:36.63
低:35.91
收:36.13
52周最高:62.58
52周最低:23.42
股本:5,810.15萬
流通股本:5,134.85萬
量比:1.34
換手率:2.89%
股息:- -
股息率:- -
每股收益(TTM):11.13
每股收益(LYR):11.86
淨資產收益率:64.05%
總資產收益率:-25.71%
市淨率:1.53
市盈率(LYR):3.04

資料載入中...

2025/03/04

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/03/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2025/02/13

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2025/02/13

重要事件披露

Form 8-K - Current report
2025/02/13

重要事件披露

Form 8-K - Current report
2025/01/13

重要事件披露

Form 8-K - Current report
2025/01/06

重要事件披露

Form 8-K - Current report
2025/01/03

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/08

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/11/07

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/10/31

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/10/31

重要事件披露

Form 8-K - Current report
2024/08/08

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]